KRAS and colorectal carcinoma: How BRAFi + EGFRi when used in combination with chemotherapy in BRAFV600E CRC and EGFRi in BRAF/KRAS wildtype CRC alters cell plasticity and whether cell plasticity contributes to therapy resistance in these settings are important areas of future research.